Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02913612
Recruitment Status : Recruiting
First Posted : September 26, 2016
Last Update Posted : November 2, 2018
The EMMES Corporation
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Chiara Melloni, Duke University

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 28, 2019
  Estimated Study Completion Date : September 28, 2019